Last reviewed · How we verify
Biological: COVID-19 convalescent plasma
Biological: COVID-19 convalescent plasma is a Biologic drug developed by Nakhle Saba, MD. It is currently in Phase 2 development for Treatment of COVID-19 in adults and pediatric patients.
COVID-19 convalescent plasma contains antibodies that help the body fight COVID-19 infection.
COVID-19 convalescent plasma contains antibodies that help the body fight COVID-19 infection. Used for Treatment of COVID-19 in adults and pediatric patients.
At a glance
| Generic name | Biological: COVID-19 convalescent plasma |
|---|---|
| Sponsor | Nakhle Saba, MD |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
Convalescent plasma is derived from the blood of individuals who have recovered from COVID-19 and contains antibodies against the SARS-CoV-2 virus. These antibodies can provide passive immunity to individuals who are infected with COVID-19, helping to reduce the severity of symptoms and the risk of complications.
Approved indications
- Treatment of COVID-19 in adults and pediatric patients
Common side effects
- Thrombosis
- Allergic reactions
- Fatigue
Key clinical trials
- Intermediate IND Severe Illness COVID-19 CP (PHASE1)
- Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Convalescent Plasma for COVID-19 Patients (EARLY_PHASE1)
- Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
- CoVID-19 Plasma in Treatment of COVID-19 Patients (EARLY_PHASE1)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- COVID-19 Convalescent Plasma (CCP) Transfusion (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological: COVID-19 convalescent plasma CI brief — competitive landscape report
- Biological: COVID-19 convalescent plasma updates RSS · CI watch RSS
- Nakhle Saba, MD portfolio CI
Frequently asked questions about Biological: COVID-19 convalescent plasma
What is Biological: COVID-19 convalescent plasma?
How does Biological: COVID-19 convalescent plasma work?
What is Biological: COVID-19 convalescent plasma used for?
Who makes Biological: COVID-19 convalescent plasma?
What development phase is Biological: COVID-19 convalescent plasma in?
What are the side effects of Biological: COVID-19 convalescent plasma?
Related
- Manufacturer: Nakhle Saba, MD — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of COVID-19 in adults and pediatric patients
- Compare: Biological: COVID-19 convalescent plasma vs similar drugs
- Pricing: Biological: COVID-19 convalescent plasma cost, discount & access